A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

开始日期2025-01-01

申办/合作机构

Albert B. Sabin Vaccine Institute, Inc.

[+1]

NCT05817422 / Active, not recruiting临床2期IIT

开始日期2023-10-19

申办/合作机构

Albert B. Sabin Vaccine Institute, Inc.

[+1]

NCT04723602 / Completed临床1期IIT

Phase 1b Trial to Evaluate Safety, Tolerability and Immune Responses of 2 Monovalent Chimpanzee Adenoviral Vectored Filovirus (Ebola-S and Marburg) Vaccines to Healthy Adults, Collection of Plasma/Serum for the Purposes of Assay Development

Primary Objective:
• To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
Secondary Objectives:
To evaluate the antibody response to Monovalent Chimpanzee Adenoviral Vectored Filovirus Ebola-S (cAd3-EBO-S) and Monovalent Chimpanzee Adenoviral Vectored Filovirus (Marburg) (cAd3 Marburg) vaccines as assessed by antigen glycoprotein (GP) specific (enzyme-linked immunosorbent assay) ELISA
To collect sufficient post-vaccination plasma to support further development of filovirus assays

开始日期2021-01-06

申办/合作机构

Albert B. Sabin Vaccine Institute, Inc.

[+2]

100 项与 VRC-MARADC087-00-VP 相关的临床结果

登录后查看更多信息

100 项与 VRC-MARADC087-00-VP 相关的转化医学

登录后查看更多信息

100 项与 VRC-MARADC087-00-VP 相关的专利（医药）

登录后查看更多信息

项与 VRC-MARADC087-00-VP 相关的文献（医药）

2023-01-01·The Lancet1区 · 医学

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

1区 · 医学

Article

作者: Preston, Anne ; Ploquin, Aurélie ; Stanley, Daphne A ; Vazquez, Sandra ; Ortega-Villa, Ana M ; Kioko, Victoria ; Coates, Emily E ; Ledgerwood, Julie E ; Holman, LaSonji A ; Thillainathan, Jagada ; Flach, Britta ; Scott, Paul T ; Widge, Alicia T ; Augustine, Brooke ; McDermott, Adrian B ; McCauley, Melanie D ; Cox, Josephine H ; Yamshchikov, Galina V ; Storme, Casey ; Basappa, Manjula ; Andrews, Charla ; Gordon, Ingelise J ; Lee, Christine ; Happe, Myra ; Hickman, Somia ; Koup, Richard A ; Trofymenko, Olga ; O'Connell, Sarah ; Murray, Tamar ; Gall, Jason G ; Amare, Mihret F ; Ake, Julie A ; Sullivan, Nancy J ; Hutter, Jack N ; Waterman, Paige E ; Padilla, Marcelino ; Robb, Merlin L ; Modjarrad, Kayvon ; Hunegnaw, Ruth ; Morgan, Patricia ; Strom, Larisa ; Narpala, Sandeep R ; Dulan, Caitlyn N M ; Gaudinski, Martin R ; Schech, Steven ; Hamer, Melinda J ; Swanson, Phillip A ; Houser, Katherine V ; Hofstetter, Amelia R ; Mascola, John R

BACKGROUNDWHO has identified Marburg virus as an emerging virus requiring urgent vaccine research and development, particularly due to its recent emergence in Ghana. We report results from a first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (cAd3-Marburg) in healthy adults.METHODSWe did a first-in-human, phase 1, open-label, dose-escalation trial of the cAd3-Marburg vaccine at the Walter Reed Army Institute of Research Clinical Trials Center in the USA. Healthy adults aged 18-50 years were assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 10¹⁰ or 1 × 10¹¹ particle units (pu). Primary safety endpoints included reactogenicity assessed for the first 7 days and all adverse events assessed for 28 days after vaccination. Secondary immunogenicity endpoints were assessment of binding antibody responses and T-cell responses against the Marburg virus glycoprotein insert, and assessment of neutralising antibody responses against the cAd3 vector 4 weeks after vaccination. This study is registered with ClinicalTrials.gov, NCT03475056.FINDINGSBetween Oct 9, 2018, and Jan 31, 2019, 40 healthy adults were enrolled and assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 10¹⁰ pu (n=20) or 1 × 10¹¹ pu (n=20). The cAd3-Marburg vaccine was safe, well tolerated, and immunogenic. All enrolled participants received cAd3-Marburg vaccine, with 37 (93%) participants completing follow-up visits; two (5%) participants moved from the area and one (3%) was lost to follow-up. No serious adverse events related to vaccination occurred. Mild to moderate reactogenicity was observed after vaccination, with symptoms of injection site pain and tenderness (27 [68%] of 40 participants), malaise (18 [45%] of 40 participants), headache (17 [43%] of 40 participants), and myalgia (14 [35%] of 40 participants) most commonly reported. Glycoprotein-specific antibodies were induced in 38 (95%) of 40 participants 4 weeks after vaccination, with geometric mean titres of 421 [95% CI 209-846] in the 1 × 10¹⁰ pu group and 545 [276-1078] in the 1 × 10¹¹ pu group, and remained significantly elevated at 48 weeks compared with baseline titres (39 [95% CI 13-119] in the 1 ×10¹⁰ pu group and 27 [95-156] in the 1 ×10¹¹ pu group; both p<0·0001). T-cell responses to the glycoprotein insert and neutralising responses against the cAd3 vector were also increased at 4 weeks after vaccination.INTERPRETATIONThis first-in-human trial of this cAd3-Marburg vaccine showed the agent is safe and immunogenic, with a safety profile similar to previously tested cAd3-vectored filovirus vaccines. 95% of participants produced a glycoprotein-specific antibody response at 4 weeks after a single vaccination, which remained in 70% of participants at 48 weeks. These findings represent a crucial step in the development of a vaccine for emergency deployment against a re-emerging pathogen that has recently expanded its reach to new regions.FUNDINGNational Institutes of Health.

Vaccines

Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine

Article

作者: Burkholz, Scott ; Herst, Charles V. ; Harris, Paul E. ; Rubsamen, Reid M.

The Marburg virus (MARV), the virus responsible for Marburg hemorrhagic fever (MHF), is considered a top-priority pathogen for vaccine development. Recent outbreaks in Equatorial Africa have highlighted the urgency of MARV because of its high fatality rate and historical concerns about potential weaponization. Currently, there are no licensed vaccines for MARV. Existing vaccine candidates rely on attenuated recombinant vesicular stomatitis virus carrying MARV glycoprotein (VSVΔG) or the chimpanzee replication-defective adenovirus 3 vector ChAd3-MARV. Although these platforms provide significant protection in animal models, they face challenges because of their limited thermal stability and the need for cold storage during deployment in resource-poor areas. An alternative approach involves using adjuvanted poly (lactic-co-glycolic acid) (PLGA) microparticles loaded with synthetic peptides representing MHC class I—restricted T cell epitopes. This vaccine platform has demonstrated effectiveness in protecting against SARS-CoV-2 and EBoV disease in animal models and has the advantage of not requiring cold storage and remaining stable at room temperature for over six months. This report outlines the design, manufacturing, and in vivo immunogenicity testing of PLGA microparticle human vaccines designed to prevent Marburg hemorrhagic fever.

项与 VRC-MARADC087-00-VP 相关的新闻（医药）

2023-01-30

·Science Daily

Marburg vaccine shows promising results in first-in-human study

A new article shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine could someday be an important tool to respond to Marburg virus outbreaks. A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine, developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, could someday be an important tool to respond to Marburg virus outbreaks. This first-in-human, Phase 1 study tested an experimental MARV vaccine candidate, known as cAd3-Marburg, which was developed at NIAID's Vaccine Research Center (VRC). This vaccine uses a modified chimpanzee adenovirus called cAd3, which can no longer replicate or infect cells, and displays a glycoprotein found on the surface of MARV to induce immune responses against the virus. The cAd3 vaccine platform demonstrated a good safety pro prior clinical trials when used in investigational Ebola virus and Sudan virus vaccines developed by the VRC. MARV, a filovirus in the same family as Ebola virus, causes a rapidly progressive febrile illness that leads to shock and death in a large proportion of infected individuals. Many scientists think that MARV disease outbreaks in humans begin by when the virus makes the jump from its primary animal host, which is likely to be certain chronically infected bats in sub-Saharan Africa. The symptoms of MARV disease are akin to those seen with Ebola virus disease and can include fever, headache, chills, rash, abdominal pain, vomiting, and diarrhea. As the disease progresses, patients may suffer from multiple organ dysfunction, delirium, and significant bleeding from the gastrointestinal tract or other sites that may result in death. No approved vaccines or specific therapies are available for MARV disease, aside from supportive care. While some experimental vaccines have previously been tested, none have proven to be both highly effective and to provide durable protection. In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of time would be a crucial part of quelling outbreaks. In this study, 40 healthy adult volunteers were enrolled at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, Maryland. They received a single dose of either a low dose of the vaccine (1x1010 particle units) or a higher dose (1x1011 particle units). For safety, the volunteers were enrolled in a dose-escalation plan. Three participants received the lower dose. Then, when they did not exhibit severe adverse reactions after the first seven days, the trial proceeded to enroll the remaining 17 volunteers. The same procedure was also used for the higher dose group. Volunteers were monitored for adverse reactions to the investigational vaccine and evaluated at regular intervals for 48 weeks to track their immune responses. The trial's safety results were encouraging: There were no serious adverse events, and the experimental vaccine was well-tolerated. One participant in the higher dose group developed a fever following vaccination, but it resolved by the following day. In addition, the investigational vaccine appeared to induce strong, long-lasting immunity to the MARV glycoprotein: 95% of participants in the trial exhibited a robust antibody response after vaccination, and 70% maintained that response for more than 48 weeks. Plans are in place to conduct further trials of the cAd3-Marburg vaccine in Ghana, Kenya, Uganda, and the United States. If additional data supports the promising results seen in the Phase 1 trial, the cAd3-Marburg virus vaccine could someday be used in emergency responses to MARV outbreaks.

疫苗临床1期临床结果

2021-06-17

·GlobeNewswire

Marburg Virus Disease Pipeline Offers Promising New Options

Los Angeles, USA, June 16, 2021 (GLOBE NEWSWIRE) -- Marburg Virus Disease Pipeline Offers Promising New Options for Treatment Around 12+ key companies are developing the Marburg Virus Disease therapies. Bavarian Nordic is developing the MVA-BN filovirus vaccine, which is in the most advanced stage. DelveInsight’s “Marburg Virus Disease Pipeline Insight” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Marburg Virus Disease pipeline landscapes. It comprises Marburg Virus Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Marburg Virus Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Marburg Virus Disease pipeline products. Some of the key takeaways from the Marburg Virus Disease Pipeline Report Get an overview of pipeline landscape @ Marburg Virus Disease Clinical Trials Analysis Marburg Virus Disease is a highly virulent disease, which causes hemorrhagic fever. It belongs to the same family that causes Ebola virus disease. There is no particular treatment for Marburg hemorrhagic fever. Instead, supportive hospital therapy should be utilized, including balancing the patient’s fluids and electrolytes, maintaining oxygen status and blood pressure, replacing lost blood and clotting factors, and treating any complicating infections. Marburg Virus Disease Emerging Drugs Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the virus treatment. BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, NIAID contracted with BioCryst to develop galidesivir to treat Marburg Virus Disease and potentially for other filoviruses, including the Ebola virus. The drug is currently in phase 1 of clinical trials for the treatment of Marburg Virus Disease. Research and Development Phase I NCT03800173: BioCryst Pharmaceuticals, in December 2018, initiated “A Phase 1 Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Galidesivir (BCX4430) Administered as Single Doses Via Intravenous Infusion in Healthy Subjects”. This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion. This single ascending dose study will assess the safety, tolerability, and PK of single doses of galidesivir vs. placebo administered as IV infusions in healthy subjects enrolled in up to four dose cohorts of 8 subjects each. A single dose of study drug will be administered per cohort: 6 subjects will receive galidesivir IV, and two subjects will receive matching placebo. The trial got completed in April 2019 with 32 enrolled participants. Results MVA-BN Filo is a multivalent vaccine candidate designed to protect against the most common causes of viral hemorrhagic fever; Ebola and the Marburg virus. While several sub-types of Ebola are known, the vaccine targets the Zaire and Sudan strains, which are considered the most important from a public health perspective in addition various. It is currently in phase 2 of clinical trials for the treatment of Marburg Virus Disease. cAd3-Marburg, also known as VRC MARADC087 00 VP, is being developed and investigated by Albert B. Sabin Vaccine Institute, ICON plc, and Oklahoma Blood Institute in Phase I stage of development for the treatment of patients with Marburg virus disease. Research and Development Phase INCT04723602: In January 2021, a trial was initiated by ICON plc in collaboration with Sabin vaccine institute titled “Phase 1b Trial to Evaluate Safety, Tolerability and Immune Responses of 2 Monovalent Chimpanzee Adenoviral Vectored Filovirus (Ebola-S and Marburg) Vaccines to Healthy Adults, Collection of Plasma/Serum for the Purposes of Assay Development”. The primary objective is to evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults. The trial is anticipated to get completed in December 2021 with an estimated enrollment of 32 participants. For further information, refer to the detailed report @ Marburg Virus Disease Pipeline Therapeutics Scope of Marburg Virus Disease Pipeline Drug Insight · Marburg Virus Disease Therapies Late-stage (Phase III) · Marburg Virus Disease Therapies Mid-stage (Phase II)· Marburg Virus Disease Therapies Early-stage (Phase I) · Marburg Virus Disease Pre-clinical stage and Discovery candidates · Discontinued and Inactive candidates · RNA replicase inhibitors· Immunostimulants· Virus replication inhibitors · Peptides· Monoclonal Antibody· Polymer· Small molecule· Gene therapy · Oral· Parenteral· Intravenous· Subcutaneous· Topical · Monotherapy· Combination· Mono/Combination Key Questions regarding Current Marburg Virus Disease Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customized pipeline report @ Marburg Virus Disease Drugs Pipeline Report Related Reports DelveInsight's 'Central Venous Catheters Market Insights, Competitive Landscape and Market Forecast-2026' report delivers an in-depth understanding of Central Venous Catheters. DelveInsight’s Juvenile Idiopathic Arthritis (JIA) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Keloid - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. "Oncolytic Virus Cancer Therapy" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. Capnography Devices Market Insights, Competitive Landscape, and Market Forecast-2026 report delivers an in-depth understanding of Capnography Devices and the historical and forecasted epidemiology. Cardiac Resynchronization Therapy Market Insights, Competitive Landscape, and Market Forecast-2026 report delivers an in-depth understanding of Cardiac Resynchronization Therapy. About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

基因疗法抗体疫苗小分子药物合作

100 项与 VRC-MARADC087-00-VP 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
马尔堡病毒病	临床2期	肯尼亚	Albert B. Sabin Vaccine Institute, Inc.	2023-10-19
马尔堡病毒病	临床2期	乌干达	Albert B. Sabin Vaccine Institute, Inc.	2023-10-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03475056 (RV 507, CTgov)	临床1期	马尔堡病毒病	40	cAd3-Marburg vaccine (Group 1: cAd3-Marburg Vaccine (1x10^10 PU))	遞衊願襯繭糧窪積築夢(廠鏇網鑰夢築築製蓋簾) = 築齋齋衊衊壓蓋窪鬱網選蓋構願艱積願選顧淵 (積淵衊夢淵鬱壓壓鏇簾, 選鹽選憲鹹憲選積鹽製 ~ 鏇鹹糧廠選鏇範鬱鏇壓) 更多	-	2021-01-14
				cAd3-Marburg vaccine (Group 2: cAd3-Marburg Vaccine (1x10^11 PU))	遞衊願襯繭糧窪積築夢(廠鏇網鑰夢築築製蓋簾) = 淵餘醖壓鏇憲窪鏇醖範選蓋構願艱積願選顧淵 (積淵衊夢淵鬱壓壓鏇簾, 願膚遞獵獵餘窪壓網衊 ~ 鹽鹽範鏇鹽觸選製築範) 更多